USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 3, 2004. USANA Health Sciences, Inc. develops, manufactures, and distributes nutritional and personal care products through a network marketing system (Direct Selling) and operates a Contract Manufacturing segment. As of the period end, the company had approximately 96,000 active Associates and 55,000 active Preferred Customers globally.
Key Financial Metrics
| Metric | Q1 2004 (Ended Apr 3) | Q1 2003 (Ended Mar 29) |
|---|---|---|
| Net Sales | $61,775,000 | $40,864,000 |
| Gross Profit | $46,717,000 | $31,644,000 |
| Gross Margin | 75.6% | 77.4% |
| Net Earnings | $6,213,000 | $3,575,000 |
| Diluted EPS | $0.30 | $0.17 |
| Operating Cash Flow | $7,795,000 | $7,139,000 |
| Cash and Equivalents (End of Period) | $14,861,000 | $5,485,000 |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 51.2% year-over-year, driven by a 47.4% increase in the Direct Selling segment and the addition of the Contract Manufacturing segment.
- Profitability: Net earnings rose 73.8% to $6.2 million. Diluted EPS increased 76.5% to $0.30.
- Customer Base: Active Associates grew 37.1% to 96,000, and active Preferred Customers grew 17.0% to 55,000.
- Geographic Expansion: New markets in South Korea, Singapore, and Mexico contributed approximately $4.0 million in sales, which were not present in the prior year.
- Acquisition: The company acquired FMG Productions, LLC in February 2004 for $2.1 million to enhance training and promotional materials.
- Share Repurchases: The company spent $8.2 million to repurchase 285,000 shares of common stock during the quarter.
Guidance, Outlook, and Risks
- Guidance: Management expects consolidated net sales to exceed $65 million for the second quarter of 2004. Full-year fiscal 2004 sales are projected in the range of $255 million to $260 million.
- Outlook: Gross profit margins in the Contract Manufacturing segment are expected to improve modestly in the second quarter. Selling, general, and administrative expenses are expected to increase in absolute terms but improve as a percentage of sales.
- Liquidity: The company canceled its $10 million line of credit in April 2004 and is negotiating a new facility. Management believes current cash and operating cash flows are sufficient for foreseeable needs.
- Risks: Key risks include dependence on the network marketing model, high Associate turnover, foreign currency fluctuations (53.6% of sales are international), and reliance on outside suppliers for raw materials (specifically CoQ10 shortages).
Investor Verification Checklist
- Verify the sustainability of the 37.1% growth in the active Associate base.
- Monitor the impact of CoQ10 raw material shortages on future gross margins.
- Confirm the terms and availability of the new line of credit following the cancellation of the previous $10 million facility.
- Assess the integration and financial contribution of the FMG Productions acquisition.
- Review the effectiveness of the share repurchase program and its impact on diluted EPS.